Drugs / FLANVOTUMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01137006 | Jun 2010 → Aug 2012 | melanoma | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLANVOTUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108734 ↗ |
| Known as | 20-D-7S | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108734 ↗ |
| Known as | IMC-20D7S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01137006 ↗ |
| Modality | Monoclonal antibody | “Anti-gp75 Monoclonal Antibody IMC-20D7S” NCT01137006 ↗ |
| Route | Intravenous | “administered intravenously (i.v.)” NCT01137006 ↗ |
| Target | TYRP1 | “5,6-dihydroxyindole-2-carboxylic acid oxidase other” CHEMBL2108734 ↗ |